Answers are grounded in this paper and cite their sources.
Sir, Pulmonary haemorrhage (PH) is a rare complication of SLE with a reported frequency ranging from 1 to 5.4%, and mortality up to 92% [1]. There is general agreement that combination treatment with high-dose corticosteroids (CS) and cyclophosphamide (CYC) must be initiated early with an additional benefit with plasma exchange (PEx) shown in some small case series [2, 3]. It is important to note that, however, some studies showed no improvement in survival with early use of CYC [1] or addition of PEx [4]. Furthermore, these treatments carry the risk of significant side effects in this group of patients, particularly those with concurrent infections. Therefore, there is a real need to identify more effective treatments with fewer side effects in this group of severely affected patients. Increasingly, B-cell depletion with rituximab (RTX) has been used to treat various manifestations of SLE including secondary treatment of SLE-PH when initial therapy with CS, CYC and PEx had failed [5]. We report the successful early treatment of SLE-PH with RTX and CYC in a 52-year-old woman with a 12-year history of SLE (characterized by malar rash, leucopenia, positive ANA, negative ENA, positive dsDNA antibodies and grade IV lupus nephritis). The nephritis had been treated successfully with i.v. pulsed methylprednisolone and CYC (total dose 7.5 g) 8 years before. Thereafter, her SLE remained quiescent and immunosuppression was tapered with the treatment using prednisolone 3 mg/day alone with no additional therapy for lupus. She was admitted to our hospital with acute abdominal pain. Initial investigations revealed lymphopenia [0.94 (NR 1.5–4.0) × 109/l], thrombocytopenia [136 (NR 150–400) × 109/l], elevated CRP [37 (NR < 5) mg/l], hypocomplementaemia [C3 0.47 (NR 0.9–1.8) g/l and C4 < 0.04 (NR 0.10–0.40) g/l] and raised anti-dsDNA antibodies [178 (DNA ELISA, NR 0–50) IU/ml] (Fig. 1). A full immunological profile revealed a low titre of ANA (1:40), negative ENA, aCL and lupus anticoagulant. Stool, urine and blood cultures were negative. Her admission chest radiograph was normal. Abdominal CT revealed intestinal mural thickening with peritoneal-free fluid consistent with a vasculitic or infective process. Alterations in clinical and laboratory parameters during the first 18 days of admission. The gastrointestinal symptoms improved with conservative management. On the third day of her admission, however, she developed a dry cough, tachypnoea and bibasal crepitations. Her haemoglobin fell and arterial blood sampling revealed type 1 respiratory failure (Fig. 1). A CT pulmonary angiogram demonstrated upper lobe pulmonary infiltrates consistent with infection or focal haemorrhage, but no pulmonary emboli. I.v. broad spectrum antibiotics and methylprednisolone (total 3 g) were commenced. Despite an initial clinical improvement, her respiratory function deteriorated on Day 7 requiring non-invasive ventilation with a further drop in haemoglobin and platelets (Fig. 1). Bronchoscopy confirmed PH with no evidence of infection. Following a three unit blood transfusion, i.v. RTX (1000 mg) was given on Days 9 and 25 and a single dose of i.v. CYC (750 mg) on Day 10 leading to a rapid clinical improvement in respiratory function and cytopaenias (Fig. 1). CRP and dsDNA titres normalized within 1 month. B-cell depletion was confirmed 2 weeks post-RTX with a CD19 count of 0.002 (normal 0.03–0.40) × 109/l. She was subsequently discharged home on prednisolone 40 mg/day which has been gradually reduced to 7.5 mg/day over the subsequent 3 months and she has returned to normal physical activities with no evidence of active lupus. Her disease remains in clinical and serological remission 16 months post-discharge, despite the repopulation of B cells (CD19 0.039 × 109/l) at 10 months. There has been only one previously published case report of the use of RTX in a patient with SLE-PH [5], which was used as a salvage measure when initial therapy with CS, CYC and PEx had failed. In contrast, we report for the first time the successful use of B-cell depletion therapy as a part of the early treatment regimen for PH in SLE also complicated by gastrointestinal involvement. Interestingly, we noted an early (resolution of cytopenias within the first week) and sustained improvement (fall in anti-dsDNA antibodies from 1 month) in both the clinical and laboratory features of our patient’s illness following the administration of CYC and RTX (Fig. 1). A similarly rapid response within the first month of RTX treatment has been observed in other diseases, such as relapsing remitting multiple sclerosis [6] and refractory ITP [7]. These observations, coupled with our own, provide important insights into the mechanism of action of B-cell depletion. RTX does not target mature plasma cells, therefore it is unlikely that a reduction in the number of pathological autoantibodies—which may take several weeks or months to become apparent—can explain these rapid treatment effects. Given that circulating B-cell depletion normally occurs within 48 h of administration of RTX [8], it is likely that loss of B-cell-mediated antigen presentation, cytokine production or T-cell regulation is the therapeutic target leading to the early improvement observed post-RTX [9]. Detailed pharmacokinetic studies are required to delineate the mechanism of response to RTX in patients with autoimmune diseases and its precise role in SLE-related PH. We believe that such studies are warranted given the successful outcome reported in our case. We wish to thank Dr Mark Pugh, Consultant Rheumatologist, St Mary’s Hospital, Newport, Isle of Wight, UK, for help with preparation of the manuscript. Disclosure statement: D.A.I. has consulted for Roche, Merck-Serono, Teva, Bristol Myers Squibb and Celltech. He does not accept personal renumeration from these companies and asks that the honoraria are paid to a local arthritis charity. All other authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Narshi et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: